The invention discloses an application of IOX1 in prevention and / or treatment of autoimmune diseases, and particularly relates to an application of IOX1 in control of Th17-mediated in-vivo
inflammation. The inventor screens an epigenetic compound concentration
library of an inhibitor for expression of IFN-gamma and IL-17 in Th1 and Th17 cultures, screens and determines that IOX1 is an effective inhibitor for expression of IL-17 in CD4+T cells, and also finds that the IOX1 inhibits expression of I117a by directly targeting activity of TET2 to a
promoter in Th17 cells. The inventor further proves that IOX1 plays an anti-inflammatory role
in vivo by regulating migration and functions of Th17 cells through a
uveitis model, and Th17-mediated in-vivo
inflammation can be effectively controlled.